|
|
|
|
|
(State or other jurisdiction of incorporation or organization)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
|
Address Not Applicable1
|
ZIP Code Not Applicable
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a‑12 under the Exchange Act (17 CFR 240.14a‑12)
|
|
Pre‑commencement communications pursuant to Rule 14d‑2(b) under the Exchange Act (17 CFR 240.14d‑2(b))
|
|
Pre‑commencement communications pursuant to Rule 13e‑4(c) under the Exchange Act (17 CFR 240.13e‑4(c))
|
|
Title of each class
|
Trading
Symbol(s)
|
Name of each exchange
on which registered
|
||
|
|
|
(Nasdaq Capital Market)
|
| Item 7.01 |
Regulation FD Disclosure
|
| Item 9.01 |
Financial Statements and Exhibits.
|
|
Exhibit No.
|
Description
|
|
|
Remix Therapeutics, Inc. press release, dated November 19, 2026.
|
||
| 104 |
Cover Page Interactive Data File (embedded within the Inline XBRL document).
|
|
PASSAGE BIO, INC.
|
||
|
Date: November 19, 2026
|
By:
|
/s/ Kathleen Borthwick
|
|
Kathleen Borthwick
|
||
|
Chief Financial Officer
|
||